Key clinical point: Energy-based therapy with adjunctive oxymetazoline was safe and improved facial erythema for patients with moderate to severe facial erythema associated with rosacea.
Major finding: Among 43 evaluable patients, clinician erythema assessment score was improved in 39 (90.7%) patients 6 hours post treatment and in 30 (68.2%) patients pretreatment.
Study details: An open-label, phase 4 study of 46 patients with moderate to severe facial erythema associated with rosacea.
Disclosures: The manuscript was funded by oxymetazoline manufacturer Aclaris Therapeutics. Several authors disclosed being an investigator, consultant, and/or laser manufacturers. One author was an employee of Aclaris at the time of the study.
FROM LASERS IN SURGERY AND MEDICINE
This Week's Must Reads
Must Reads in Rosacea
Mental Health Burden of Acne Vulgaris and Rosacea, Clin Exp Dermatol; ePub 2019 Jan 31; Singam, et al